Translate Bio to Present at Upcoming Investor Conferences
February 19 2020 - 7:30AM
Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA)
therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or
gene dysfunction, today announced that Ronald Renaud, chief
executive officer, will present a corporate overview at the
following upcoming investor conferences:
- 9th Annual SVB Leerink Partners Global Healthcare Conference on
Wednesday, February 26, 2020, at 2:30 p.m. ET at the Lotte New York
Palace.
- 40th Annual Cowen and Company Health Care Conference on Monday,
March 2, 2020, at 11:20 a.m. ET at the Boston Marriott Copley
Place.
A live webcast of each
presentation will be accessible through the “Events and
Presentations” page of the Company's website at
investors.translate.bio. A replay of the webcast will be archived
on the Translate Bio’s website for 30 days following the
presentation.
About Translate BioTranslate
Bio is a clinical-stage mRNA therapeutics company developing a
new class of potentially transformative medicines to treat diseases
caused by protein or gene dysfunction. The Company’s MRT platform
is designed to develop product candidates that deliver mRNA
carrying instructions to produce intracellular, transmembrane and
secreted proteins for therapeutic benefit. Translate
Bio is primarily focused on applying its MRT platform to treat
pulmonary diseases caused by insufficient protein production or
where production of proteins can modify disease. The Company also
believes its technology is applicable to a broad range of diseases,
including diseases that affect the liver, eye and central nervous
system. Additionally, the MRT platform may be applied to various
classes of treatments, such as therapeutic antibodies or vaccines
in areas such as infectious disease and oncology. Translate Bio’s
lead program is being developed as a treatment for cystic fibrosis
(CF) and is in an ongoing Phase 1/2 clinical trial. For more
information about the Company, please visit
www.translate.bio or on Twitter at @TranslateBio.
Contacts for Translate Bio
Investors |
|
Media |
Teri Dahlman |
|
Maura Gavaghan |
tdahlman@translate.bio |
|
mgavaghan@translate.bio |
857-242-7792 |
|
857-242-7789 |
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024